Recent blog posts
SEMA7A Biologics Sequence Review Report 2026: Semaphorin-7A Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SEMA7A Biologics Sequence Review Report 2026: Semaphorin-7A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA7A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA6B Biologics Sequence Review Report 2026: Semaphorin-6B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SEMA6B Biologics Sequence Review Report 2026: Semaphorin-6B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ADAM5 Biologics Sequence Review Report 2026: Putative disintegrin and metalloproteinase domain-containing protein 5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ADAM5 Biologics Sequence Review Report 2026: Putative disintegrin and metalloproteinase domain-containing protein 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Spontaneous bacterial peritonitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Spontaneous bacterial peritonitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Spontaneous bacterial peritonitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Refractory ascites Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Refractory ascites Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Refractory ascites indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Minimal hepatic encephalopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Minimal hepatic encephalopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Minimal hepatic encephalopathy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Crigler-Najjar syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Crigler-Najjar syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Crigler-Najjar syndrome type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Progressive familial intrahepatic cholestasis type 5 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Progressive familial intrahepatic cholestasis type 5 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Progressive familial intrahepatic cholestasis type 5 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Read →
Congenital portosystemic shunt Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Congenital portosystemic shunt Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Congenital portosystemic shunt strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Classic galactosemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Classic galactosemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Classic galactosemia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Progressive familial intrahepatic cholestasis type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Progressive familial intrahepatic cholestasis type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Progressive familial intrahepatic cholestasis type 4 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Read →
Alagille syndrome liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Alagille syndrome liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Alagille syndrome liver disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →